Brand Name(s): Asendin
CAS nš: 14028-44-5
(ah mock sa peen)
About Amoxapine
This new site is dedicated exclusively to amoxapine.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or a pharma industry professional, you can now find out everything you need to know about amoxapine on this reference site, as well as take part in our open discussion forum by sharing your own knowledge and experience with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total amoxapine experience!
Why is this medication prescribed?
Amoxapine is in a class of drugs called tricyclic antidepressants. It affects chemicals in the brain that may become unbalanced and cause depression.
This medicine is used to relieve symptoms of depression such as feelings of sadness, worthlessness, guilt, loss of interest in daily activities, changes in appetite, tiredness, sleeping too much, insomnia, and thoughts of death or suicide.
Latest News
Solid-phase extraction and analysis of 20 antidepressant drugs in human plasma by LC/MS with SSI method
A simultaneous determination of 20 antidepressant drugs (imipramine, amitriptyline, desipramine,...
[more]Tri-cyclic Anti-depressants that Can Cause Tinnitus
Of all the tri-cyclic anti-depressants, Clomipramine is probably the worst in regards to tinnitus...
[more]Reports Phase 2 Data On CRx-150 In Human Inflammatory Disease Model; Periodontitis Trial Fails Main Goal
Cambridge, Mass.--(Business Wire)--CombinatoRx, Incorporated (NASDAQ: CRXX - News) today announced...
[more]CombinatoRx reports preliminary data for drug candidate CRx-119 does not meet primary endpoint
CombinatoRx, Incorporated (CRXX) announced preliminary results of its randomized, blinded,...
[more]